“Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies”. SKIN The Journal of Cutaneous Medicine 2, no. S1 (February 23, 2018): S16. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/307.